This guide to Skyrizi explains what the medicine is used for, how it is intended to work, and which benefits and risks readers should understand. In the context of immune and inflammatory conditions, the right choice depends on the condition being treated, the product formulation, other medicines, and a person’s medical history. Use the sections below to prepare informed questions for a clinician or pharmacist, not to diagnose yourself or change a prescribed treatment.
Because it blocks a single target rather than broadly damping immunity, Skyrizi is often described as a precision therapy. That focus still carries real precautions, which is why prescribers screen for infections such as tuberculosis before the first dose and set clear rules around vaccines.
This guide explains what Skyrizi treats, how it works inside the immune system, what the injections and infusions look like in practice, the side effects people report most often, and the safety checks that come with starting a biologic.
What Is Skyrizi?
Skyrizi is the brand name for risankizumab, a monoclonal antibody classified as an interleukin-23 (IL-23) inhibitor. A monoclonal antibody is a laboratory-built protein designed to attach to one precise target in the body. Here, the target is the p19 subunit of IL-23, a signaling protein that helps keep chronic inflammation switched on.
The drug is prescription only and never sold over the counter. It is not a steroid, not a painkiller, and not a conventional disease-modifying pill such as methotrexate. A specialist — usually a dermatologist, rheumatologist, or gastroenterologist — manages treatment, sets the schedule, and monitors the response over time.
As a biologic, it is grown from living cell systems instead of being assembled from small chemical building blocks. That origin explains both the price of modern immunology drugs and the careful refrigerated handling their storage demands.
What Is Skyrizi Used For?
Skyrizi carries FDA approval for several immune-mediated conditions. For adults with moderate-to-severe plaque psoriasis, it is approved for people who are candidates for systemic medicines or light-based treatments such as phototherapy. For active psoriatic arthritis, it is approved to reduce the signs and symptoms of the disease, and prescribers sometimes pair it with another medicine such as methotrexate when they believe the combination helps.
The label also covers moderately-to-severely active Crohn’s disease and, with labeling expanded in recent years, ulcerative colitis — the two main forms of inflammatory bowel disease. Because those approvals arrived in stages, it is sensible to check the most current prescribing information or ask your gastroenterologist directly whether Skyrizi fits your situation.
Any use outside these approved conditions counts as off-label. Specialists do study biologics in other immune diseases, but evidence, insurance coverage, and safety oversight differ outside the label. Raise off-label questions with your own prescriber, who can weigh your medical history against what the data actually support.
How Does Skyrizi Work?
The immune system coordinates its response to injury and infection through chemical messengers called cytokines. In psoriasis, psoriatic arthritis, and inflammatory bowel disease, one of those messengers — interleukin-23 — stays active long after the original trigger is gone, repeatedly delivering what amounts to a “keep the inflammation coming” signal.
Skyrizi intercepts that messenger. The drug binds to IL-23 before it can dock on cell receptors, so the inflammatory chain reaction it would normally trigger slows down. Skin cells stop being pushed to mature too quickly, swollen joint lining settles, and the intestinal lining gets room to recover.
The IL-23 pathway has a supporting cast worth knowing. Interleukin-23 helps maintain a population of immune cells called Th17 cells, which in turn release other inflammatory messengers — including the interleukin-17 that rival drugs target. Interrupting IL-23 upstream therefore eases an entire cascade rather than one downstream voice, which is one reason this drug class earned a place in both dermatology and gastroenterology.
What makes this approach distinctive is its narrowness. Older immunosuppressants broadly quiet the immune system; an IL-23 inhibitor leaves most immune functions untouched. That is the core idea behind biologic therapy — engineered proteins that mirror parts of the body’s own signaling toolkit and switch off one pathway instead of many.
Available Forms and Strengths
Skyrizi is supplied as prefilled pens and prefilled syringes for injection under the skin, plus an intravenous formulation used in a clinic to begin treatment for Crohn’s disease and ulcerative colitis. Exact strengths and doses are set by the prescriber, so the table below describes the general pattern rather than specific amounts.
| Form | Where it is given | How the schedule usually flows |
|---|---|---|
| Prefilled pen | Self-injection at home, after clinic training | Starting doses spaced a few weeks apart, then a maintenance injection every 8 or 12 weeks depending on the condition |
| Prefilled syringe | Self-injection at home for people who prefer a syringe | Same start-then-maintain rhythm as the pen |
| IV infusion | Infusion center or clinic | A short series of infusions to start treatment for Crohn’s disease or ulcerative colitis, followed by under-the-skin maintenance doses |
The every-8-week or every-12-week maintenance rhythm means far fewer injections than daily or weekly medicines, though the exact cadence depends on the condition being treated. Before you begin, the prescribing office or infusion team will write out your personal calendar so nothing is left to guesswork.
Choosing between the pen and the syringe is usually a comfort call. The pen hides the needle and many people find it steadier for one-handed use; the syringe suits those who want to see the dose or who learned injections with a needle. Both deliver the same medicine, and switching between them later is a routine request — just confirm it with the clinic so your training stays current.
How to Take Skyrizi
Home injections go under the skin of the thigh, abdomen, or upper arm, and the site rotates with each dose to keep any one spot from getting sore. The clinic walks you or a caregiver through the first injection, and the manufacturer supplies step-by-step training materials. Most people let the pen or syringe sit at room temperature before injecting, following the package instructions, because a dose straight from the refrigerator can sting more.
Keep an injection log — date, site, and any reaction — whether in a notebook or the manufacturer’s app. It settles questions about when the last dose happened, helps the clinic rotate sites sensibly, and gives follow-up visits something concrete to review. Most prescribers also schedule periodic check-ins while you are on therapy, so the log doubles as a running record of how the plan is actually going.
If You Miss a Dose
A delayed maintenance dose is not an emergency. Call the prescribing office, tell them when your last dose was and when you noticed the gap, and follow their timing advice. Never stack two injections to catch up — doubling a biologic does not repair a missed week and only raises side-effect risk.
Overdose and Emergency Help
If someone receives more Skyrizi than prescribed, contact the prescriber or call Poison Control at 1-800-222-1222, and seek emergency care if any symptoms look serious. There is no at-home remedy for an extra dose of a biologic, so professional guidance is the safe route.
Common Side Effects
Day to day, the effects reported most often are colds and other upper respiratory infections, headaches, fatigue, reactions at the injection site, and joint pain. Injection-related effects — redness, mild swelling, or tenderness — usually settle within a few days of the needle.
| Side effect | What it can feel like | A practical response |
|---|---|---|
| Upper respiratory infections | Stuffy nose, sore throat, mild cough | Rest and fluids; call the clinic if it lingers or worsens |
| Headache | Dull or pressing pain | Report if headaches become frequent or severe |
| Fatigue | Low energy, unusual sleepiness | Note the pattern and mention it at your next visit |
| Injection site reactions | Redness, itching, or swelling where the needle went in | Rotate sites and follow the injection training steps |
| Joint pain | Aching in one or more joints | Mention at the next appointment, sooner if it is new and intense |
None of these are reasons to stop treatment on your own. Care teams would rather hear about a small symptom early than untangle a bigger problem later.
Serious Side Effects and Warnings
Like other biologics, Skyrizi can allow serious infections to take hold, including tuberculosis that has been dormant for years. That is why testing happens before the first dose — and why any fever, chills, lasting cough, night sweats, unexplained weight loss, or warm, red skin sore should be reported quickly. Rarely, liver injury has been reported in people taking the drug, so yellowing of the skin or eyes, dark urine, or nausea paired with unusual tiredness deserves a prompt call.
- Trouble breathing, throat tightness, swelling of the face, lips, or tongue, or widespread hives: these can signal a serious allergic reaction — call emergency services.
- Fever with a productive cough or shortness of breath: a possible lung infection; contact the clinic the same day.
- Draining skin sores or painful, spreading swelling: a possible deep infection; do not wait it out.
- Yellow eyes or skin, dark urine, or pain near the right ribs: possible liver involvement; call promptly.
Live vaccines — certain shingles, measles-containing, and nasal-spray flu formulations among them — should not be given while on Skyrizi, because the drug blunts the immune response a live vaccine depends on. Plan any needed vaccinations with the care team before treatment starts.
Who Should Use Skyrizi with Caution?
Most people who reach biologic therapy do well with it, but a few groups need extra planning rather than an automatic pass. The sections below cover the main situations that change the conversation with your specialist.
Drug and Vaccine Interactions
Prescribers generally avoid combining Skyrizi with other biologic immunosuppressants, because layered immune effects raise infection risk. Non-live vaccines are usually acceptable, though the response may be somewhat weaker during treatment. Bring a complete list of prescription medicines, over-the-counter products, and supplements to every visit so the team can spot conflicts early.
Pregnancy and Breastfeeding
Information on risankizumab during pregnancy is limited, so decisions are made case by case. Some people with active psoriasis or inflammatory bowel disease continue treatment because uncontrolled disease carries its own risks; others pause it. Tell your prescriber as soon as pregnancy is planned or confirmed, and do not stop the medication on your own first.
Use in Children and Older Adults
Skyrizi’s approved uses center on adults, and its record in children is shorter than that of older biologic classes. Ask the specialist whether current labeling covers your child’s condition. Older adults often carry a higher baseline risk of infection, which usually means more thorough screening and follow-up rather than treatment being ruled out.
Storage and Handling
Keep pens and syringes refrigerated in their original carton, never in the freezer, and shielded from light. If a dose has been frozen or left in a hot car, ask the pharmacist or clinic whether it is still usable instead of guessing. For travel, an insulated pouch keeps the temperature steady and the carton protects the label.
Used needles and pens belong in an FDA-cleared sharps container, not the household trash. Your clinic or pharmacy can explain the disposal rules that apply locally.
How Quickly It Works and How Long It Lasts
Timelines differ by condition. With plaque psoriasis, some people notice their skin settling within the first several weeks, with clearer results accumulating over the following months of maintenance doses. Joint symptoms tend to move more slowly, and healing in Crohn’s disease or ulcerative colitis is judged by the care team during and after the infusion-based starting phase.
Because the drug clears gradually, its effect persists between the widely spaced doses. That same slow clearance is why stopping and restarting should always be a prescriber-guided decision — symptoms can return, and a second course does not always work as smoothly as the first.
Alternatives and Comparisons
Skyrizi sits in a crowded and genuinely useful field. TNF-blocker biologics such as adalimumab (Humira) have decades of use across skin, joint, and bowel disease. IL-17 inhibitors such as secukinumab (Cosentyx) are strong options for psoriasis, psoriatic arthritis, and axial spondyloarthritis. Oral choices include apremilast (Otezla), a PDE4 inhibitor pill, and upadacitinib (Rinvoq), a once-daily JAK inhibitor.
Conventional systemics such as methotrexate remain first-line tools for many people, and topical treatments handle milder skin disease. Which option wins depends on the specific condition, severity, other health problems, pregnancy plans, insurance coverage, and simply how a person prefers to take medicine. An IL-23 inhibitor is one well-regarded route among several — not the only road to control.
Frequently Asked Questions
These are the questions specialists hear most often about Skyrizi. Use the answers as conversation starters with your own care team rather than as personal medical advice.
Is Skyrizi a steroid?
No. It contains no corticosteroid and does not cause steroid-type effects such as weight gain, bone thinning, or facial rounding. It is a targeted biologic protein that blocks a single immune messenger.
How often will I need a dose once treatment is established?
For the under-the-skin maintenance phase, injections typically land every 8 or 12 weeks, with the interval depending on the condition and the prescriber’s plan. Crohn’s disease and ulcerative colitis usually begin with clinic infusions before switching to home injections.
Why is a tuberculosis test required before starting?
Blocking IL-23 can allow a dormant tuberculosis infection to wake up. A skin or blood test — sometimes paired with a chest X-ray — finds hidden infection so it can be treated before the biologic begins.
Can I get a flu shot while using Skyrizi?
Standard injected flu vaccines are generally fine, though timing is worth discussing with the care team. Live nasal-spray flu vaccines should be avoided during treatment.
Does Skyrizi shut down the whole immune system?
No. It blocks one specific signaling protein rather than the entire immune apparatus. Infection risk still rises enough to matter, which is why screening and prompt symptom reporting are part of the deal.
How is Skyrizi different from methotrexate?
Methotrexate is an older, broadly acting oral or injected medicine used across many immune conditions; Skyrizi is an engineered antibody that blocks one messenger, IL-23. The two differ in side-effect profiles, monitoring needs, and pregnancy considerations, and in some conditions they are even used together under specialist supervision.
What happens if I stop taking it?
Disease activity often returns over time, and restarting later does not always work as well as the first course. Any pause should be planned with the prescriber, ideally with a plan for managing flares in the meantime.
Conclusion
Skyrizi reflects where autoimmune care has landed: fewer, more precise treatments that interrupt specific messengers instead of blanket-suppressing the body. Its approvals now span skin, joints, and the gut, and the every-8-or-12-week maintenance rhythm is manageable once established. Success still leans on the unglamorous basics — tuberculosis screening, vaccine planning, honest symptom reporting, and steady follow-up. Bring your questions to the specialist; a well-informed patient is the best partner a biologic can have.
Medical Disclaimer
This content is general health information, not a prescription or a diagnosis.
Medical Disclaimer: This article is for informational and educational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Follow the official product instructions and seek urgent medical assistance for a medical emergency.
References and Sources
- DailyMed — Skyrizi (risankizumab) drug information — official labeling, forms, and safety details.
- MedlinePlus Drug Information — plain-language drug resources from the National Library of Medicine.
- Drugs@FDA — FDA approval records and labeling history for risankizumab.
- Official Skyrizi website — manufacturer information on uses, injection training, and support programs.